Lundbeck

40

DKK

-0,65 %

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Mindre end 1K følgere

-0,65%

-3,19%

-1,72%

-15,79%

+0,25%

+16,08%

+22,62%

-28,9%

+62,6%

Lundbeck er en farmaceutisk virksomhed. Det største fokus findes i forskning om psykiatriske og neurotiske lidelser, som omfatter behandling af depression, skizofreni, Alzheimers og Parkinsons syndrom. Virksomheden driver forskning, udvikling og videre distribution af lægemidler, hvor kunder findes på globalt plan. Virksomheden blev grundlagt i 1915 og har sit hovedkontor med beliggenhed i Valby.

Markedsværdi

39,83 mia. DKK

Aktieomsætning

12,34 mio. DKK

Omsætning

19,91 mia.

EBIT %

16,05 %

P/E

17,32

Udbytteafkast, %

1,75 %

Finanskalender

5.2

2025

Årsrapport '24

26.3

2025

Generalforsamling '25

14.5

2025

Delårsrapport Q1'25

ViserAlle indholdstyper

Selskabsmeddelelse9.1.2025, 13.07

H. Lundbeck A/S: Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD

Pressemeddelelse5.12.2024, 12.00

H. Lundbeck A/S: Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations

Pressemeddelelse3.12.2024, 07.00

H. Lundbeck A/S: Efficacy of Vyepti highlighted by new clinical trial results in severe migraine

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse2.12.2024, 14.08

H. Lundbeck A/S: Lundbeck completes acquisition of Longboard

Selskabsmeddelelse28.11.2024, 06.56

H. Lundbeck A/S: Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled

Pressemeddelelse27.11.2024, 07.00

H. Lundbeck A/S: Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy

Selskabsmeddelelse13.11.2024, 06.29

H. Lundbeck A/S: Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024

Selskabsmeddelelse31.10.2024, 11.44

H. Lundbeck A/S: Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention

Pressemeddelelse23.10.2024, 07.01

H. Lundbeck A/S: Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth

Selskabsmeddelelse14.10.2024, 10.30

H. Lundbeck A/S: Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline

Pressemeddelelse3.10.2024, 07.00

H. Lundbeck A/S: Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease

Pressemeddelelse27.9.2024, 12.00

H. Lundbeck A/S: Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Pressemeddelelse26.9.2024, 10.00

H. Lundbeck A/S: Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery

Selskabsmeddelelse20.8.2024, 07.09

H. Lundbeck A/S: Lundbeck raised financial guidance following strong growth (+19% CER) from strategic brands, on path towards becoming a Focused Innovator

Selskabsmeddelelse20.8.2024, 06.53

H. Lundbeck A/S: Lundbeck raises financial guidance for 2024

Pressemeddelelse31.7.2024, 06.00

H. Lundbeck A/S: Lundbeck and Takeda modify the collaboration agreement for Trintellix in the U.S.

Selskabsmeddelelse25.6.2024, 05.59

H. Lundbeck A/S: Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)

Pressemeddelelse19.6.2024, 06.30

H. Lundbeck A/S: Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing's disease trial

Pressemeddelelse3.6.2024, 12.00

H. Lundbeck A/S: Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia

Selskabsmeddelelse15.5.2024, 05.31

H. Lundbeck A/S: Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.